Recent News

• 04.09.2025 - TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
• 03.21.2025 - TCBP Announces Transition from Nasdaq to OTC Markets
• 03.18.2025 - TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
• 03.05.2025 - TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
• 02.20.2025 - TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
• 02.13.2025 - TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
• 02.10.2025 - TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
• 02.05.2025 - TCBP to Implement ADS Ratio Change
• 02.05.2025 - TCBP to Implement ADS Ratio Change
• 01.15.2025 - TCBP Announces H5N1 Proof of Concept Studies Intention

Recent Filings

• 03.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.21.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.10.2025 - EX-99.1 EX-99.1
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - EX-99.1 EX-99.1
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]